MARKET

HMTXF

HMTXF

Hemostemix
OTCMQB
0.066
NaN%
Closed 09:30 02/20 EST
OPEN
--
PREV CLOSE
0.066
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.210
52 WEEK LOW
0.050
MARKET CAP
12.93M
P/E (TTM)
-3.0648
1D
5D
1M
3M
1Y
5Y
1D
Hemostemix Inc. ernennt Dr. York Hsiang zum Business Consultant
Reuters · 02/03 18:11
Hemostemix Appoints Dr. York Hsiang as Business Consultant
Reuters · 02/03 18:11
Hemostemix plant Joint Venture mit First Nations zur Errichtung von Gesundheitszentren
Reuters · 02/03 13:56
Hemostemix Partners with First Nations to Establish Healthcare Centres
Reuters · 02/03 13:56
Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships
Newsfile · 02/03 13:55
Hemostemix Receives FDA Support for Basket Protocol Approach
Reuters · 01/16 17:27
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
Newsfile · 12/31/2025 19:38
Hemostemix Appoints Dr. David B. Alper to Lead Physician Education and Join Scientific Advisory Board
Reuters · 12/23/2025 14:11
More
About HMTXF
Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.

Webull offers Hemostemix Inc stock information, including OTCMQB: HMTXF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HMTXF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HMTXF stock methods without spending real money on the virtual paper trading platform.